RxDoctor Payments Data

Diane Rosaly

Family · Dickinson, TXNPI 1144730573

Payments from drug & device makers

$2,352in general payments, 2019–2025

Across 123 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$426
  • AbbVie$392
  • AstraZeneca$348
  • Lilly USA, LLC$343
  • Exact Sciences$143
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$112
  • plus $589 from 18 others

What the payments were for

  • Food & beverage$2,352100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,352 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$11,214
Medicare patients
45
Services billed
322

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$32,276
LinzessLinaclotide12$5,741
Albuterol Sulfate HfaAlbuterol Sulfate22$817
Estradiol11$816
Levothyroxine Sodium81$755
Trazodone Hcl31$701
Escitalopram Oxalate36$697
Gabapentin33$611
Atorvastatin Calcium101$595
ProgesteroneProgesterone, Micronized14$548
Omeprazole45$512
Venlafaxine Hcl ErVenlafaxine Hcl14$450
Duloxetine Hcl19$407
Pravastatin Sodium36$392
Hydroxyzine Hcl16$384

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$426$32,27625 claims
AbbVieLinzess$392$5,74112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.

Other family in Dickinson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →